Press
Releases
Press Releases
AVROBIO Announces Preclinical Gene Therapy Data for Pompe Disease at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
Genetically modified hematopoietic stem cells lead to supraphysiological levels of therapeutic protein in a mouse model of Pompe disease sustained at eight months after administration Substantial reduction in glycogen observed across cardiac and skeletal muscles, as well as CNS Data support plans
May 18, 2022
AVROBIO Reports Positive Data From Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures
New early data show key visual motor integration, visual perception and motor coordination measures impacted by cystinosis stabilized or improved post gene therapy Systemic reach of AVR-RD-04 observed across multiple other measures All five dosed patients remain off oral cysteamine post gene
May 17, 2022
AVROBIO to Present at the H.C. Wainwright Global Investment Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 16, 2022-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced members of its senior management team will be presenting virtually at the H.C.
May 16, 2022
AVROBIO Reports First Quarter 2022 Financial Results and Provides Business Update
Phase 1/2 collaborator-sponsored 1 clinical trial in cystinosis fully enrolled New interim cystinosis clinical data to be presented at the 25 th annual meeting of the American Society of Gene and Cell Therapy (ASGCT) Multiple regulatory interactions planned in 2022 to inform clinical development
May 10, 2022
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 6, 2022-- AVROBIO , Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that the company has granted a non-statutory stock option for the purchase of up to
May 06, 2022
AVROBIO to Present New Clinical and Preclinical Data at the ASGCT 25th Annual Meeting
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 3, 2022-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that new data from its ongoing, collaborator-sponsored 1 Phase 1/2 clinical trial
May 03, 2022
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 6, 2022-- AVROBIO , Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted a non-statutory stock option for the purchase of up to
Apr 06, 2022
AVROBIO to Present at the 21st Annual Needham Virtual Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 5, 2022-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced Geoff MacKay , president and CEO of AVROBIO , will present at the 21 st Annual
Apr 05, 2022
AVROBIO Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update
Provided interim data at WORLDSymposium™ 2022 that showed sustained engraftment across first three patients 1 + year post-gene therapy in Phase 1/2 clinical trial i for cystinosis; all remain off oral cysteamine to date Interim clinical data update of AVR-RD-02 in Gaucher disease type 1 planned
Mar 17, 2022
AVROBIO to Present at Two Upcoming Investor Conferences in March
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 1, 2022-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in two
Mar 01, 2022
Displaying 1 - 10 of 17